Key result
Advanced NSCLC in men is linked to ~21% lower pretreatment serum IGF-1 levels versus controls.
Why the study?
The clinical significance of pretreatment serum levels of IGF-1 and IGFBP-3 in advanced stage NSCLC and their contribution to clinical evaluations was unclear.
Are pretreatment serum levels of IGF-1 and IGFBP-3 altered in men with advanced non-small cell lung cancer compared to healthy controls?
Case-Control (n=80)
Yes
Are pretreatment serum levels of IGF-1 and IGFBP-3 altered in men with advanced non-small cell lung cancer compared to healthy controls?
Pretreatment serum levels of IGF-1 and the IGF-1/IGFBP-3 ratio are significantly lower in men with advanced NSCLC and may serve as useful diagnostic markers.
Answers are grounded in this paper and cite their sources.
Lower IGF-1 levels and ratio were associated with advanced NSCLC and histologic subtype; leaves open diagnostic utility pending prospective validation.
Objective: Insulin- like growth factor-1 (IGF-1) regulates a number of cellular functions such as proliferation and differentiation. On the other hand, insulin-like growth factor binding protein-3 (IGFBP-3) is a putative tumor suppressor and inhibits the proliferative activity of IGF-I. Therefore most studies report that IGF-I and IGFBP-3 may promote and inhibit tumor growth, respectively. In this study we aimed to evaluate the importance of IGF-1 and IGFBP-3 in advanced stage non-small cell lung cancer (NSCLC) and to find out whether they contribute to clinical evaluations. Material and Methods: We measured the pretreatment serum levels of IGF-1 and IGFBP-3 in 80 men between July 2007 and June 2008 by chemiluminescent immunometric assay. Serum samples were obtained from 50 patients with inoperable advanced stage NSCLC at Dr. Suat Seren Pulmonary Diseases Hospital and 30 healthy controls at Izmir Tepecik Research Hospital. All 80 men had a smoking history of minimum 20 pack/years. Results: Contrary to the results of many reports, the serum IGF-1 levels were lower in the patients and the difference between the groups reached a statistical significance (p=0.025). IGF-1/IGFBP-3 ratio was also significantly lower in lung cancer patients (p=0.016). The histological subtype of tumor was correlated with IGF-1 level (p=0.005). Conclusion: Our result showed that serum level of IGF-I/IGFBPs may be useful markers for diagnosing and identifying tumor subtypes in NSCLC. In addition, IGF-1 and IGFBP-3 levels in serum might serve a clinical significance in patients with advanced stage NSCLC. However, further studies comprising more cases are needed to investigate the clinical significance of IGF-1 and IGFBP-3 in NSCLC.
No takes yet. Share an insight, caveat, or question.
Çolak et al. (2012) conducted a case-control in Advanced Non-Small Cell Lung Cancer (n=80). Advanced non-small cell lung cancer vs. Healthy controls was evaluated on Pretreatment serum IGF-1 levels (ng/ml) (p=0.025). Pretreatment serum IGF-1 levels were lower in men with advanced non-small cell lung cancer compared to healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: